Pharmaceutical serialization and anti-counterfeiting

Pci pharma services offers clinical services which includes clinical trial manufacturing. Features: it includes manufacturing a range of dosage forms in compliance with current gmp standards. Contact us for more information.

Pci pharma services offers clinical services which includes clinical trial packaging. Features: it includes primary packaging, secondary packaging, design & development, specialty product packaging. Contact us for more information.

Pci pharma services offers commercial services which includes commercial manufacturing. Features: it includes dispensing facilities, granulation, compress tablets, capsule,coating, semisolids and oral liquids preparations. Contact us for more information.

Pci pharma services offers commercial services which includes commercial packaging. Features: it include packaging for large-scale projects requiring sophisticated integrated technologies and automation. It includes primary packaging and secondary packaging. Contact us for more information.

Pci pharma services offers commercial services which includes contained potent drug manufacturing. Features: its equipment include high shear granulation, contained roller compactor granulation, fluid bed drying, milling/blending, tablet compression, encapsulation, contained xcelodose® drug in capsule/vial...

Pci pharma services offers clinical services which includes pharmaceutical development. Features: it includes early stage formulation and analytical development, drug in capsule/vial using xcelodose® technology, scale-up and stability testing process validation, technology transfer and all associated analy...

3

5

6

7

Pci pharma services offers clinical services which includes biological derivatives. Features: it is used in treatments of a number of diseases and injuries. Contact us for more information.

Pci pharma services offers clinical services which includes clinical planning support. Features: it has elements which includes project management, ivrs-iwrs, qualified persons, support services, data access via webflow. Contact us for more information.

The first-of-its-kind centre will offer biopharma clients convenience and efficiencies in the rapidly expanding Northeast

Targeted protein degraders (TPDs), including PROTACs and molecular glues, represent a transformative therapeutic approach but face significant challenges in oral delivery due to their size, polarity, and poor solubility. Enhancing bioavailability is therefore critical to unlocking their full clinical potential. In this presentation, David O’Connell, Director of Scientific Affairs at PCI Pharma Services, will explore the latest bioavailability enhancement strategies for TPDs, from hot melt extrusion and nanomilling to advanced spray drying and nanotechnology. He will also highlight PCI’s strategic partnerships with leading solubility experts, enabling integrated, end-to-end solutions that accelerate development and improve outcomes for complex molecules.

With over fifty years of packaging expertise and in excess of 50 successful product launches per year, PCI is a trusted leader and industry expert in the commercialization of new medicines.

Pharmaceutical companies face continued pressure to develop and commercialize their medicines. PCI Clinical Services is committed to supporting clients at every stage of the clinical cycle, delivering best-in-class services efficiently and effectively.

Through the acquisition of Penn Pharma, PCI has significant experience in providing integrated drug development, clinical trial supply and commercial manufacturing of solid dose,liquid and semi-solid potent products to high standards of safety and quality.